6 completed, 1 active not recruiting, 1 recruiting, 1 unknown. 3 Phase 3, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Active not recruiting 1 |
| Phase 2 | 1 | Unknown 1 |
| Phase 4 | 1 | Completed 1 |
Follow NovoSeven: new trials by email Literature Review of NovoSeven trials Research Report on NovoSeven
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial Recombinant Activated Factor VII (rFVIIa), Placebo - Intracerebral Hemorrhage | Phase 3 | Active not recruiting | Joseph Broderick, MD | 860 | 2021-12-03 | 2026-01-21 |
| NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL Eptacog alfa, Standard of care - Post Partum Hemorrhage | Completed | Leiden University Medical Center | 3322 | 2020-05-01 | 2022-05-11 | |
| Treatment of Hemophilia A Patients With FVIII Inhibitors Nuwiq, Octanate, Wilate - Hemophilia A | Recruiting | Emory University | 120 | 2020-03-17 | 2026-09-23 | |
| Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia NovoSeven - Massive Hemorrhage, Massive Blood Loss | Completed | Universiti Sains Malaysia | 76 | 2017-08-21 | 2018-10-10 | |
| Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency Eptacog alfa, biosimilar, Novoseven - Factor VII Deficiency | Phase 3 | Completed | AryoGen Pharmed Co. | 24 | 2017-03-01 | 2021-02-04 |
| rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors recombinant activated factor VII - Hemophilia A With Inhibitors | Phase 2 | Unknown | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 50 | 2010-12-01 | 2013-04-08 |
| Treatment of Inherited Factor VII Deficiency plasma derived Factor VII, recombinant FVIIa, Fresh Frozen Plasma - Factor VII Deficiency | Completed | University of L'Aquila | 223 | 2007-01-01 | 2012-11-27 | |
| Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII rFVIIa-FEIBA therapy for hemophilia A inhibitors, FEIBA- Activated Prothrombin Complexes - Hemophilia A | Phase 4 | Completed | Sheba Medical Center | 5 | 2005-01-01 | 2012-07-27 |
| Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation NovoSeven - Hemophilia A | Phase 3 | Completed | Medical University of Vienna | 2007-04-20 |
Hemophilia A (4) · Factor VII Deficiency (2) · Cerebral Hemorrhage (1) · Hematologic Diseases (1) · Postpartum Hemorrhage (1) · Thrombocytopenia (1)
AryoGen Pharmed Co. (1) · Emory University (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Joseph Broderick, MD (1) · Leiden University Medical Center (1) · Medical University of Vienna (1) · Sheba Medical Center (1) · Universiti Sains Malaysia (1) · University of L'Aquila (1)
Germany (3) · United States (3) · Italy (2) · Spain (2) · Austria (1) · Canada (1) · France (1) · Iran (1) · Japan (1) · Malaysia (1) · Netherlands (1) · Romania (1) · United Kingdom (1)
Catherine Deneux-Tharaux, MD, PhD (1) · Chong Soon Eu, MD, MMed (1) · Dacia Henriquez, MD, PhD (1) · Elena Santagostino, MD, PhD (1) · Hellen Edwards, MD, PhD (1) · Joseph Broderick, MD (1) · Marian Knight, MD, PhD (1) · Massimo Iacobelli, MD (1) · Nan van Geloven, PhD (1) · Nurfatin Mohd Shah, BSc (1) · Robert Sidonio, MD, MSc (1) · Sabine Eichinger, MD (1) · Thomas van den Akker, MD, PhD (1)
PMID 23403322, PMID 24763923, PMID 34427473, PMID 34589194, PMID 37870112, PMID 39654449, PMID 41653933
2019 (1), U01NS110772 (1)